525 filings
6-K
CANF
Can-Fite Biopharma Ltd
15 Dec 20
Report of Foreign Private Issuer
7:06am
6-K
CANF
Can-Fite Biopharma Ltd
14 Dec 20
Can-Fite Reports on Progress with its Namodenoson NASH Program
7:06am
6-K
CANF
Can-Fite Biopharma Ltd
9 Dec 20
Report of Foreign Private Issuer
4:32pm
6-K
CANF
Can-Fite Biopharma Ltd
2 Dec 20
Report of Foreign Private Issuer
4:30pm
6-K
CANF
Can-Fite Biopharma Ltd
30 Nov 20
Can-Fite Reports Third Quarter 2020 Financial Results & Provides Clinical Update
7:12am
6-K
penk93xa2xz0
24 Nov 20
Report of Foreign Private
7:07am
6-K
6e0o5qe1c djidqhok5
16 Nov 20
Report of Foreign Private Issuer
7:04am
F-6EF
yma 4gnovj49
6 Nov 20
Automatic registration for ADRs (foreign)
4:32pm
6-K
5ickbanlpw6k
28 Oct 20
Report of Foreign Private Issuer
4:31pm
6-K
cvaed3
13 Oct 20
Key Opinion Leader in the Treatment of Psoriasis to Join the Presentation and Q&A
7:08am
EFFECT
wna0s
13 Oct 20
Notice of effectiveness
12:15am
CORRESP
2wqqn74 vmbsz
7 Oct 20
Correspondence with SEC
12:00am
6-K
v7nnlx0ya2r6jdtiu
6 Oct 20
Can-Fite Announces Positive Phase III Psoriasis Interim Data Analysis
7:41am
UPLOAD
9l8qjkmqkmk5v2zza39
2 Oct 20
Letter from SEC
12:00am
6-K
69i4ut9
30 Sep 20
Principal Investigator Prof. Rifaat Safadi to present Namodenoson’s Phase II results at highly prestigious scientific conference for liver diseases
7:12am
F-3
4mi55gptnly1x 385
25 Sep 20
Shelf registration (foreign)
4:37pm
EFFECT
4djzr
8 Sep 20
Notice of effectiveness
12:15am
6-K
ax26g755
31 Aug 20
Report of Foreign Private Issuer
7:10am
POS AM
epg myx5ot0p486
28 Aug 20
Prospectus update (post-effective amendment)
4:33pm
6-K
xhn9xp2
27 Aug 20
Report of Foreign Private Issuer
7:10am